ISO 9001 CERTIFIED QMS · UKAS-VERIFIED THIRD-PARTY TESTING · HPLC-VERIFIED PER BATCH
✓ HPLC-verified per batch ✓ CoA with every order ✓ 2-3 day Ireland delivery ✓ ISO 9001 certified

PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.

Fast Ireland delivery — dispatched to Dublin, Cork, Galway, Limerick and nationwide.

Cerebrolysin — Ireland Research Reference (2026)

HPRA regulatory notice: Peptides Lab Ireland supplies all compounds strictly for in-vitro laboratory and scientific research. They are not licensed medicines and are not for human or veterinary use.

Cerebrolysin is unusual among research compounds. It is not a single, defined peptide but a mixture of small peptides and amino acids prepared from pig brain proteins. It has been studied for decades in models of stroke, brain injury and neurodegeneration, and it is registered as a medicine in a number of countries, though not in Ireland. This guide explains, in plain English, what Cerebrolysin is, how it is made, what the research shows, why its mixed nature makes it tricky to study, and what Irish labs should consider when sourcing it.

What is Cerebrolysin?

Cerebrolysin is a preparation made by breaking down purified proteins from pig brain with enzymes, under controlled conditions. The result is a solution containing a mixture of low-molecular-weight peptides and free amino acids. The peptide fraction is generally described as having molecular weights below about 10,000 daltons.

It was developed in Austria in the mid-twentieth century and has been in clinical use in a number of countries since then, mainly in Central and Eastern Europe and parts of Asia. It is not a licensed medicine in Ireland, and products sold here as research compounds are for laboratory use only.

Why is Cerebrolysin called a “neurotrophic” preparation?

Neurotrophic factors are proteins that support the growth, survival and maintenance of nerve cells. The best-known examples are brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF).

Cerebrolysin is described as having neurotrophic-like activity, meaning that in research models it appears to mimic some of the effects of these natural factors. Researchers have proposed that some of the peptides in the mixture act on the same signalling pathways as natural neurotrophic factors, though exactly which components do what is not fully known.

What does the research on Cerebrolysin show?

Stroke models

Stroke is the most studied area. In animal models, Cerebrolysin has been reported to reduce some markers of damage and to support recovery of movement. A 2022 review in the Journal of Clinical Medicine brings together both the preclinical and the clinical stroke findings and discusses how Cerebrolysin is thought to act [1]. These studies look at changes in brain tissue, new blood vessel growth, and the brain’s ability to rewire itself, known as neuroplasticity.

Clinical trials in people have also been carried out for stroke, with mixed results. A Cochrane review, which pools the results of controlled trials, looked at the human evidence in acute ischaemic stroke and did not find clear benefit on its main outcomes [3]. That gap between promising animal results and less clear human results is common in neuroscience and is an important context for research.

Brain and spinal cord injury models

Researchers have studied Cerebrolysin in models of traumatic brain injury and spinal cord injury, including models combining injury with exposure to metal nanoparticles, where it was reported to reduce some markers of damage [2].

Neurodegeneration models

Cerebrolysin has been studied in animal and cell models of Alzheimer’s disease and other neurodegenerative conditions, looking at nerve-cell survival, connections between nerve cells, and the build-up of abnormal proteins.

Cell culture

In cultured nerve cells, Cerebrolysin has been reported to support survival under stress and to encourage the growth of nerve fibres.

How is Cerebrolysin studied in the lab?

Most Cerebrolysin research uses one of three approaches. In cell culture, researchers grow nerve cells or brain-derived cell lines, expose them to a stress such as low oxygen, toxins or abnormal proteins, and measure whether Cerebrolysin changes cell survival, nerve fibre growth or markers of cell damage.

In animal models, mostly in rats and mice, researchers create a controlled injury, such as a temporary blockage of a brain artery to model stroke, and then compare recovery between groups. They measure the size of the damaged area, the growth of new blood vessels and nerve connections, and behaviour, such as movement and memory tests.

A third approach looks at how Cerebrolysin changes gene and protein activity in brain tissue, using modern methods that measure thousands of molecules at once. This can help identify which pathways are affected, even if the active components of the mixture are not known.

Good design matters in all of these. Blinding, random allocation of animals and pre-registered outcomes help reduce bias, which has been a recognised problem across stroke research.

Why is a peptide mixture harder to study than a single compound?

This is the key scientific challenge with Cerebrolysin. With a single peptide, researchers know exactly what they are adding, can measure it, and can link effects to a specific receptor. With a mixture:

  • The active components are not fully defined. Many peptides are present, and it is not clear which ones matter.
  • Batch-to-batch consistency matters even more. Small differences in production could change the mix.
  • Mechanisms are hard to pin down. Effects may come from several components acting together.
  • Controls are harder to design. There is no simple “scrambled” version of a mixture.
  • Comparing studies is harder, because different preparations or batches may not be identical.

These issues do not make Cerebrolysin useless as a research tool, but they mean results need careful interpretation, and good documentation of the material used is essential.

How does Cerebrolysin compare with defined neuropeptides?

Many neuroscience labs use defined peptides instead, or alongside, because they are easier to interpret:

  • Semax, a modified ACTH fragment, linked in research to BDNF and its receptor.
  • Selank, a modified tuftsin peptide studied for anxiety-like behaviour.
  • Recombinant neurotrophic factors such as BDNF, NGF and GDNF themselves.

Our Selank vs Semax comparison explains those two compounds in detail.

What should Irish labs check when buying Cerebrolysin?

Because Cerebrolysin is a mixture, the usual single-peptide checks do not fully apply. Look for:

  • Clear identification of the product and its origin.
  • Batch numbers and a batch-specific certificate.
  • Description of the composition, such as the peptide size range and amino acid content.
  • Appearance and form, often a clear to yellowish solution.
  • Storage and expiry information.
  • Sterility or endotoxin information, if you plan cell culture work.

Our guide on how to read a peptide COA explains common fields, and you should ask the supplier for anything that is missing. Our research supply is on the Cerebrolysin product page.

How should Cerebrolysin be stored?

Cerebrolysin is usually supplied as a solution in sealed ampoules or vials rather than as a freeze-dried powder. Store it according to the label, typically refrigerated, protected from light and not frozen unless stated. Once opened, the solution should be used promptly, as it is not designed to be stored after opening. Our peptide cold-chain storage guide covers delivery and storage in more detail.

Is Cerebrolysin legal in Ireland?

Cerebrolysin is not a licensed medicine in Ireland, and it is not a controlled drug. It can be supplied as a research compound for laboratory work, but it must not be sold or used as a medicine or for personal use in Ireland. Its medicine status in other countries does not change that. Our HPRA explainer sets out the general rules.

What are the open questions in Cerebrolysin research?

  • Which components of the mixture are responsible for its effects.
  • How consistent the mixture is between batches and production runs.
  • Why results in animal models have not translated more clearly into human trials.
  • How it compares directly with defined neurotrophic peptides in the same models.

Frequently asked questions

What is Cerebrolysin?

It is a mixture of small peptides and amino acids made from pig brain proteins, studied for neurotrophic-like effects in research models.

Is Cerebrolysin a single peptide?

No. It is a mixture, which makes it different from most research peptides.

What is Cerebrolysin used for in research?

Mainly models of stroke, brain and spinal cord injury, and neurodegeneration.

Is Cerebrolysin a licensed medicine in Ireland?

No. It is registered in some other countries but not in Ireland.

How is Cerebrolysin different from Semax?

Semax is a single, defined seven-amino-acid peptide. Cerebrolysin is an undefined mixture.

How should Cerebrolysin be stored?

Usually refrigerated and protected from light, according to the label. Use promptly once opened.

Where can I buy Cerebrolysin in Ireland?

Research supply is available from Peptides Lab Ireland, for laboratory use only.

Why do animal and human results for Cerebrolysin differ?

This gap is common in neuroscience. Animal models cannot fully copy human brain injury, and differences in timing, study size and outcome measures all play a part.

References

  1. Role and Impact of Cerebrolysin for Ischemic Stroke Care. J Clin Med (2022). PubMed PMID 35268364
  2. Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets (2012). PubMed PMID 22229324
  3. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev (2017). PubMed PMID 28430363

For laboratory research use only. Nothing on this page is medical advice, and none of our compounds are for human or animal consumption. Questions about a batch, a Certificate of Analysis or an order can go to [email protected].

Picture of Emma Louise

Emma Louise

Chief Compliance Officer at Peptides Lab Ireland. Emma Louise leads regulatory compliance, HPRA framework interpretation, batch quality documentation and editorial standards for the Peptides Lab Ireland research reference library. All research guides are reviewed under her editorial oversight.

Receive News

Subscribe for the Updates!

✓
99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified